Dilazep dihydrochloride
Modify Date: 2025-08-27 18:26:03
Dilazep dihydrochloride structure
|
Common Name | Dilazep dihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 20153-98-4 | Molecular Weight | 677.61000 | |
| Density | N/A | Boiling Point | 646ºC at 760 mmHg | |
| Molecular Formula | C31H46Cl2N2O10 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 344.5ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Dilazep dihydrochlorideDilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides[1][2]. |
| Name | Dilazep dihydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Adenosine uptake |
| In Vitro | The uptake mechanism has been studied extensively in vitro and Dilazep, NBI and Dipyridamole have been reported to inhibit the uptake of adenosine into different cells. Of these compounds, Dilazep and NBI are almost 10 times more potent than Dipyridamole. In addition, only Dilazep is water soluble and no solubility aiding organic solvent is needed for preparing an aqueous solution[1]. |
| In Vivo | After administration of Dilazep, even low doses (0.04-0.1 mg/kg/min) of exogenous adenosine significantly increases superior mesenteric arterial conductance (SMAC) and elevates arterial plasma adenosine concentration. The increased adenosine levels were highly correlated with the increased percentage of change of SMAC and values for Rmax and EC50 were 193.4% change of SMAC and 2.8 μM, respectively. Administration of bolus doses of 8-phenyltheophylline abolishes the ability of Dilazep to potentiate vasodilation, but did not affect isoproterenol-induced relaxation[1]. Dilazep inhibits the phospholipase activation in reperfused heart mitochondria and also inhibits the lipid peroxidation caused by cerebral ischemia and reperfusion. Dilazep may prevent ischemic cerebral injury due to an increase in cerebral blood flow and/or its protective effects on vascular endothelial cell membrane[1]. |
| References |
| Boiling Point | 646ºC at 760 mmHg |
|---|---|
| Molecular Formula | C31H46Cl2N2O10 |
| Molecular Weight | 677.61000 |
| Flash Point | 344.5ºC |
| Exact Mass | 676.25300 |
| PSA | 114.46000 |
| LogP | 5.01970 |
| Vapour Pressure | 1.41E-16mmHg at 25°C |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | DI0250000 |
|
Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta.
Biochem. J. 328 , 739, (1997) Mammalian equilibrative nucleoside transporters are typically divided into two classes, es and ei, based on their sensitivity or resistance respectively to inhibition by nitrobenzylthioinosine (NBMPR)... |
|
|
Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism.
J. Pharmacol. Exp. Ther. 285 , 568, (1998) Selective inhibitors of adenosine production, degradation and transport were used to potentiate in vivo levels of adenosine and to determine the source of both basal and N-methyl-D-aspartate (NMDA)-in... |
|
|
Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.
Blood 90 , 2345-2356, (1997) Dilazep, an antiplatelet agent, is generally used as an antithrombotic drug in clinical practice. Dilazep is also known to exert cytoprotective and antioxidant effects on endothelial cells. However, i... |
| 3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate,dihydrochloride |